CoLucid Pharmaceuticals, a privately held biopharmaceutical company, has named Thomas P. Mathers its chief executive officer.
Mathers has more than 19 years of executive management, sales and marketing experience in the life sciences and medical device industry. He also serves on the board of directors for the Biotechnology Industry Organization (BIO), and as chairman of Declion Pharmaceuticals, a company he co-founded. Previously, he served as president and CEO of Peptimmune.
"Tom will lead the CoLucid team in formulating our phase III development and commercialization plans for lasmiditan," said Art Pappas, chairman of the board of directors and managing partner at Pappas Ventures.